Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (98)	4/16/1999 9:18:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 555

There's a Yahoo post (I go slumming sometimes <g>) giving more details of the CELG presentations. I've been loaded up on CELG for a while now. Peter McEnroe of HCFP/Brenner by: abjac 4347 of 4366 has issued another positive report on CELG. Although projects a 1st Qtr loss of ($0.48) anticipates that 4 Thalidomide Abstracts will be presented at Digestive Disease Week Meeting on May 19. 1) Thalidomide-Effective Therapy in Chronic Resistent Inflamatory Bowel Disease; 2) Therapudic Efficacy of Thalidamide for patients with Refractory Crohn's Disease; 3)An Open-Label, Stepwise, Dose Escalating Pilot Studty to Evaluate the Safety, Tolerance & Efficiacy of low-dose Thalidomide in the Treatment of Chronicallly-Active, Steroid-Dependant Crohn's Disease; 4) Efficacy of Thalidamide in Crohn's Disease. 1&4 are poster presentation--other 2 oral presentations. Finally earnings to be reported on or before May 12.